Form 4 for TAK TAKEDA PHARMACEUTICAL CO LTD
Accepted 2026-08-12 21:53:37 ET · period of report 2026-08-10 · accession 0001493152-26-037513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 21:53 | 2026-08-10 | TAK | Pacheco Rhonda Janice | Pres, U.S. Business Unit | S - Sale | $17.10 | -16.9K | 182.5K | -8% | -$289.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares | 2026-08-10 | S | D | 16,901 | $17.10 | 182,507 | D | — | — | (F1) Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |